Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enzon Pharmaceuticals Inc.

www.enzon.com

Latest From Enzon Pharmaceuticals Inc.

Depomed CEO, Two Board Members Out In Settlement With Investor

Starboard has been trying to replace Depomed management and add its own members to the specialty pharma company's board since at least April 2016. This is the investor's second settlement with the pain and neurology specialist.

Commercial Companies

Nascent Deal Helps Hisun Advance Innovation Goals

Zhejiang Hisun Pharmaceuticals is continuing to enrich its pipeline through in-licensing deals, most recently with Nascent, while seeking out-licensing opportunities for its growing pipeline of clinical-stage biologics. The company is also looking to expand into other emerging markets through international partnerships, an executive says.

Commercial China

Activist Investor Laser Shines On Latest Pharma Target

We don't wish to speculate on the personal reasons that prompted Bavarian Nordic A/S's executive vice president and chief development officer Dr Jim Breitmeyer to resign on Aug. 5, two days after famed short seller Sahm Adrangi's hedge fund Kerrisdale Capital turned its laser on the Danish firm. Suffice to say, his resignation releases him from what promises to be an unpleasant and drawn-out short-selling campaign.

Cancer

Deal Watch: Endo Elbows In On Valeant’s Pursuit Of Salix

Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Enzon Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Enzon Pharmaceuticals Inc.
  • Senior Management
  • Ana I Stancic, CFO, COO & Principal Exec. Officer
    Charles Conover, PhD, SVP, R&D
  • Contact Info
  • Enzon Pharmaceuticals Inc.
    Phone: (732) 980-4500
    20 Kingsbridge Rd.
    Piscataway, NJ 08854
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register